Announcements Trials

Browse Landscape

Status

Recruiting 14 Active not recruiting 7 Completed 6 Withdrawn 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Pancreatic Neoplasms 6 Sarcoma 5 Recurrence 4 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 4 Neuroblastoma 4 Multiple Myeloma 4 Breast Neoplasms 4 Melanoma 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Acute 3 Hematologic Neoplasms 3 Head and Neck Neoplasms 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Osteosarcoma 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroectodermal Tumors, Primitive 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Lymphoma 2 Insulinoma 2 Hypoglycemia 2 Hyperinsulinism 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × Desmoid Tumors × 1 year × Clear all

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡